1.

Record Nr.

UNINA9910782968303321

Autore

Owens D. G. Cunningham (David Griffith Cunningham), <1949->

Titolo

A guide to the extrapyramidal side-effects of antipsychotic drugs / / D.G. Cunningham Owens [[electronic resource]]

Pubbl/distr/stampa

Cambridge : , : Cambridge University Press, , 1999

ISBN

1-107-11115-3

1-280-15888-3

9786610158881

0-511-11716-7

0-511-00597-0

0-511-14908-5

0-511-30292-4

0-511-54416-2

0-511-05128-X

Descrizione fisica

1 online resource (x, 351 pages) : digital, PDF file(s)

Disciplina

616.8/3

Soggetti

Extrapyramidal disorders

Antipsychotic drugs - Side effects

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Title from publisher's bibliographic system (viewed on 05 Oct 2015).

Nota di bibliografia

Includes bibliographical references (p. 320-345) and index.

Nota di contenuto

Preliminaries; Contents; Preface; 1 The background; 2 Some preliminaries; 3 Acute dystonias; 4 Parkinsonism; 5 Akathisia; 6 Tardive dyskinesia; 7 Tardive and chronic dystonia; 8 Involuntary movements and schizophrenia: a limitation to the concept of tardive dyskinesia?; 9 Special populations; 10 The clinical examination; 11 An overview of some standardised recording instruments; 12 Some medicolegal and quality-of-care issues; References; Index

Sommario/riassunto

Antipsychotic drugs have revolutionised the management of major psychiatric disorders and the outcomes of those who suffer from them. They are, however, possessed of a range of adverse effects, amongst the most frequent and distressing of which are those resulting in disturbance of voluntary motor function. Extrapyramidal side effects - or E.P.S. - are still poorly recognised and not infrequently



misattributed. Despite a vast research literature, there have been few attempts to bring together both the descriptive clinical elements of these disorders and major research conclusions pertinent to routine practice. This very readable and well illustrated 1999 book seeks to rectify this in the hope of increasing clinicians' awareness of the issues and acknowledgement of their impact. This is a task made more rather than less urgent with the emergence of drugs of lower liability but which may promote subtler abnormality than standard compounds.